Seagen announces closing of $1.0 billion stock sale to merck

Bothell, wash.--(business wire)--seagen inc. (nasdaq: sgen) today announced the closing of a $1.0 billion equity investment by merck in 5.0 million newly-issued shares of seagen common stock at a price of $200 per share. the closing occurred following expiration of the waiting period under the hart-scott-rodino antitrust improvements act of 1976 (hsr act). the investment was made in connection with a global collaboration with merck to co-develop and commercialize ladiratuzumab vedotin, an inves
SGEN Ratings Summary
SGEN Quant Ranking